Skip to main content
. 2019 Apr 6;69(6):2489–2501. doi: 10.1002/hep.30519

Figure 1.

Figure 1

Study flow. A total of 135 participants, including 69 HCC and 66 healthy controls, were enrolled as an exploratory discovery cohort for evaluation of potential of serum AKR1B10 as a diagnostic marker of HCC. A training cohort was then designed to test the diagnostic value of AKR1B10 for discrimination of HCC from healthy controls and other liver diseases, followed by a validation cohort to verify the findings in the training cohort. An independent cohort of 68 surgical patients were recruited and followed up for serum AKR1B10 changes after operation. *Participants from the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University at Changsha, China. †Participants from the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University at Changsha, China; Hunan Provincial People's Hospital at Changsha, China; and the First Affiliated Hospital of University of South China at Hengyang, China.